SHIJIAZHUANG CITY, China–(BUSINESS WIRE)–Lianhua Qingwen Capsules, an innovative patent traditional Chinese medicine (TCM) is produced by China’s Yiling Pharmaceutical under the guidance of TCM Collateral Disease Theory. Yiling Pharmaceutical has invented this drug on the basis of active inheritance of TCM theories and adoption of modern medical research achievements.
The invention of Lianhua Qingwen has drawn experience from three famous ancient physicians. The 1st is Zhang Zhongjing (born in 150 A.D. and died in 215 A.D.) of the Eastern Han Dynasty, he invented the famous Maxing Shigan Decoction which has been proven pretty effective for treating exogenous infectious diseases. The 2nd is Wu Youke (born in 1582 A.D. and died in 1652 A.D.) of the Ming Dynasty, he discussed the treatment of plague diseases in Treatise on Pestilence and put forward that rhubarb could be used for the early treatment. The 3rd one is Ye Tianshi (born in 1666 A.D. and died in 1745 A.D.) of Qing Dynasty, who ever suggested that Lonicerae and Forsythiae Powder was a classical prescription for exogenous febrile diseases. The discourses of the three famous physicians had provided inspirations for the invention of Lianhua Qingwen. (Read more…)
Articles of the basic and clinical researches of Lianhua Qingwen have been published on international authoritative journals. The paper Lianhuaqingwen Exerts Anti-Viral and Anti-inflammatory Activity against Novel Coronavirus (SARS-CoV-2), published by the academician Zhong Nanshan’s team in the leading journal of pharmacology Pharmacological Research, explains the pharmacological basis of the exact efficacy of Lianhua Qingwen capsules in treatment.
Another paper was jointly published by academicians Zhong Nanshan, Li Lanjuan and Zhang Boli in Phytomedicine, an international authoritative journal of phytomedicine. It is the first paper published on an international journal for its prospective, randomized controlled multicentric clinical study on the treatment of novel coronavirus pneumonia by TCM. The study has shown that Lianhua Qingwen can obviously increase the improvement rate of the clinical symptoms such as fever, fatigue and cough; it can also obviously improve pulmonary imaging lesions, shorten the duration of symptoms, and improve the clinical cure rate.
Lianhua Qingwen has been officially launched in the Philippines on November 23. The registration number is THPR-50 and the product category is traditional herbal drugs. Now it is available in Mercury Drug, Southstar Drug and Watson.
Contacts
First name: Li
Last Name: Kristy
E-mail:kristyli@chuhaimedia.com.cn
Phone No.: +86 85962566